Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$38.95 USD
-0.92 (-2.31%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IONS 38.95 -0.92(-2.31%)
Will IONS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Other News for IONS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Replimune Group (REPL) and Roivant Sciences (ROIV)
JPMorgan biotech analysts hold an analyst/industry conference call
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)
JPMorgan biotech analysts hold an analyst/industry conference call
Ionis Pharmaceuticals Hold Rating: Balancing Promising Data and Market Challenges